ARROWHEAD PHARMACEUTICALS INC (ARWR)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for ARWR
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ARWR | Independent Director | 65 | ["Venture Partner with Bioscience Managers", "Chairman and board member of 7 Hills Pharma", "CEO of Avita Medical, Inc.", "Chief Scientific Officer of Novartis' Cell and Gene Therapy Unit", "Vice President and Global Head of Stem Cell Therapy for Novartis Pharmaceuticals Corp", "SVP and Global Head of R&D at Baxter Healthcare", "President and CEO of Cell & Gene Therapy at Novartis AG", "VP Regulatory Affairs at Novartis, Sandoz Pharmaceuticals, and Syntex Corporation", "Director of Regulatory Affairs at Schering-Plough Corporation", "Adjunct Professor at the Gates Center for Regenerative Medicine at the University of Colorado Anschutz Medical Campus", "Faculty at Houston Methodist", "Chair of the Translational Medicine Advisory Board of the Houston Methodist Research Institute", "Holds an Honors Bachelor of Science in Physics and Engineering", "PhD in Biomedical Pharmacology from the University of Guelph", "Doctor of Veterinary Medicine & Surgery from Ontario Veterinary College", "Graduate of the International Advanced Management Program at Harvard Business School"] | ["Compensation Committee (Chair)", "Nomination Committee", "Science Committee"] | 2025 |
Biography sourced from the proxy statement filing.
Dr. Perry is currently a Venture Partner with Bioscience Managers, a global venture capital firm. Dr. Perry was Chief Executive Officer of Avita Medical, Inc., a regenerative medicine company based in Valencia, CA (Nasdaq: RCEL) from 2017 to 2022. From 2014 to 2017, he served as Chief Scientific Officer of Novartis' Cell and Gene Therapy Unit, and from 2012 to 2014 he served as Vice President and Global Head of Stem Cell Therapy for Novartis Pharmaceuticals Corp., the US affiliate of Switzerland-based Novartis AG, a global pharmaceutical company. Dr. Perry has also served as SVP and Global Head of R&D at Baxter Healthcare, and as President and as CEO of Cell & Gene Therapy at Novartis AG. Earlier in his career he served as VP Regulatory Affairs at Novartis Pharmaceuticals, Sandoz Pharmaceuticals, and Syntex Corporation. He also served as Director of Regulatory Affairs at Schering-Plough Corporation. Dr. Perry also served as a Venture Partner with Bay City Capital, LLC for eight years. Dr. Perry has previously served as a board member for the following companies: Ampliphi Bioscience Corp., Gamida Cell Ltd., Targeted Genetics, Inc., American Xeno, Inc., 7 Hills Pharma, BioTransplant, Inc., ltamar Biomedical Ltd., Systemix, Inc., Genetic Therapy, Inc., Extropy Pharmaceuticals, Inc., and Pharsight Corp. Dr. Perry served as Chair of the Compensation Committee at Ampliphi Bioscience Corp., Genetic Therapy Inc., and at Gamida Cell Ltd. He has also served as a member of the Audit Committee at several biotech companies and as Chairman or member of the Nomination Committee. Dr. Perry additionally served as board Chairman at American Xeno Inc., Extropy Pharmaceuticals Inc., and at 7 Hills Pharma, Inc. Dr. Perry holds an Honors Bachelor of Science in Physics and Engineering and a Ph.D. in Biomedical Pharmacology from the University of Guelph. He also holds a Doctor of Veterinary Medicine & Surgery from the Ontario Veterinary College and is a graduate of the International Advanced Management Program at Harvard Business School. Dr. Perry currently serves as Adjunct Professor at the Gates Center for Regenerative Medicine at the University of Colorado Anschutz Medical Campus and as Faculty at Houston Methodist and Chair of the Translational Medicine Advisory Board of the Houston Methodist Research Institute. Dr. Perry s qualifications to serve on the board include his medical expertise and his extensive experience in preclinical and clinical drug development, including executive level leadership roles and directorships in several publicly held biotech companies.